Ionis Pharmaceuticals IONS Amortization Of Financing Costs
Amortization Of Financing Costs at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's amortization of financing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's amortization of financing costs?
- Ionis Pharmaceuticals (IONS) reported amortization of financing costs of $2.35M in Q1 2026.
- How has Ionis Pharmaceuticals's amortization of financing costs changed year-over-year?
- Ionis Pharmaceuticals's amortization of financing costs increased by 43.1% year-over-year, from $1.64M to $2.35M.
- What is the long-term trend for Ionis Pharmaceuticals's amortization of financing costs?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's amortization of financing costs has grown at a 8.6% compound annual growth rate (CAGR), from $4.96M to $6.91M.
- What does amortization of financing costs mean?
- The spreading of debt-related issuance costs over the life of the loan.
- How do you interpret amortization of financing costs?
- Higher values indicate significant recent debt issuance activity or high costs of capital.
- How does amortization of financing costs compare across companies?
- Standard for any company carrying significant long-term debt on its balance sheet.